Why don't we move on to, to your two abstracts?

So for the first abstract, it's gonna be the impact of outpatient CAR T-cell therapy administration on healthcare utilization in patients with hematologic malignancies.

This is brought from Dr. Suvanne Bowen at the Mayo Clinic in Rochester.

So a little background, you know, CAR T is standard care for multiple relapsed and refractory hematologic malignancies.

Um, but the post-infusion period does, you know, carry a great risk for CRS, ICANS, um, with the onset ranging from anywhere from a few days to anywhere from, you know, seven to ten days or a little bit more.

And so a lot of patients are being monitored in a hospital setting or inpatient setting, you know, somewhere from seven to, you know, fourteen days plus.

Um, and so there's, you know, so a lot of limited data, um, comparing, you know, these two settings, including, you know, some of the data just looking at CAR T in the outpatient settings at single centers, maybe a specific disease type or product specific type, um, which can limit the generalizability of this data.

Some, some sites are using, uh, like remote, uh, telemonitoring of, of vital signs, things like that to assure a safe outpatient, uh, experience.